Accelerated Clinical Trial AgreementAccelerated Clinical Trial Agreement • August 30th, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations
This Accelerated Clinical Trial (ACTA) Agreement (“Agreement”) is made as of August 31, 2018 (“Effective Date”) by and between University of Miami (“Institution”), having an address at 1320 S. Dixie Highway, Suite 650, Coral Gables, FL 33146, and Cancer Insight, LLC, a limited liability company having its principal place of business at 1422 E Grayson, 3rd Floor, San Antonio, TX 78208 (“CRO”). CRO and Institution are herein referred to collectively as “Parties.” Individually, each of CRO and Institution is a “Party.”
Clinical Trial AgreementClinical Trial Agreement • August 30th, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations
This Clinical Trial Agreement (“Agreement”) is made on 1/26/2018 (the “Effective Date”) by and between St. Joseph Heritage Healthcare (“Institution”), a California nonprofit public benefit corporation with an address at 200 W. Center Street Promenade, Suite 800, Anaheim, California 92805; Jarrod Holmes, M.D. (“Principal Investigator”), a contractor of Institution with an office located at 3555 Round Barn Circle, Santa Rosa, CA 95403, and Cancer Insight, LLC (“CRO”), a limited liability company having its principal place of business at 110 E. Houston Street, San Antonio, TX 78205. CRO, Institution and Principal Investigator are herein referred to collectively as “Parties.” Individually, each of CRO and Institution is a “Party.”
SHARE EXCHANGE AGREEMENTShare Exchange Agreement • August 30th, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations
NOW THEREFORE THIS AGREEMENT WITNESSETH THAT in consideration of the mutual promises and covenants contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby covenant and agree as follows:
Master Services AgreementMaster Services Agreement • August 30th, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations • California
This Master Services Agreement (this “Agreement”) dated March 17, 2017 (the “Effective Date”), between BriaCell Therapeutics Corporation, having a place of business at 820 Heinz Ave., Berkeley, CA 94710 (“Client”) and KBI Biopharma, Inc., having a place of business at 1101 Hamlin Road, Durham, North Carolina 27704 (“KBI Biopharma”) (Client and KBI Biopharma, each a “Party”, and collectively, the “Parties”).
Amendment #1 to Services AgreementServices Agreement • August 30th, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations
This Amendment (“Amendment”) #1 is entered into by and between the Board of Governors of the Colorado State University System, acting by and through Colorado State University, an institution of higher education of the State of Colorado, located at Fort Collins, Colorado 80523-2002 (“University”) and the Sponsor, BriaCell Therapeutics Incorporated (“Sponsor”) (Collectively referred to as “Parties”). This amendment is effective February 1, 2019.
QUALITY AGREEMENT Between BriaCell Therapeutics Corp 820 Heinz Avenue Berkley, CA 94710 And Catalent Pharma Solutions, LLC 14 Schoolhouse Road Somerset, NJ 08873, US (represented by its signing affiliates) For Oral Drug Delivery and Clinical Supply...Quality Agreement • August 30th, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations
This is a Quality Agreement for ORAL DRUG DELIVERY and CLINICAL SUPPLY SERVICES provided by Catalent Pharma Solutions. This Quality Agreement defines the duties of Catalent Pharma Solutions, LLC (CATALENT/CPS) and BriaCell Therapeutics Corp (CUSTOMER) for the supply of clinical trial materials.
CLINICAL STUDY AGREEMENTClinical Study Agreement • August 30th, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations • Texas
This Clinical Study Agreement (the “Agreement”) is entered into by and between BriaCell Therapeutics Corporation (the “Sponsor”), a publicly traded corporation with a principal place of business located at 820 Heinz Avenue, Berkeley, California 94710, and Cancer Insight, LLC (the “CRO”), a Texas limited liability company with a principal place of business located at 110 East Houston Street, San Antonio, Texas 78205 (each a “Party” and collectively, the “Parties”). The purpose of this Agreement is for Sponsor to provide Study Drug and funding to CRO to conduct a clinical Study, which is herein described and identified as “phase I/IIa trial of BriaVax in metastatic breast cancer patients” (the “Study”), and for CRO to provide Sponsor with access to the Study data and the final Study report generated through the Study. The Agreement shall be made effective as of the last day of signature (“Effective Date”). The Parties agree as follows:
FIRST AMENDMENT TO THE CLINICAL TRIAL AGREEMENTClinical Trial Agreement • August 30th, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations
This First Amendment to the Clinical Trial Agreement (“First Amendment”) is made on August 28, 2018 (“Effective Date”) by and between Cancer Center of Kansas (“Institution”) and Cancer Insight, LLC (“CRO”). CRO and Institution are herein referred to collectively as “Parties.” Individually, each of CRO and Institution is a “Party.”
UC DAVIS STEM CELL PROGRAM SERVICES AGREEMENTStem Cell Program Services Agreement • August 30th, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations • California
This UC Davis Stem Cell Program Services Agreement (“Agreement”) is made by and between The Regents of the University of California, a corporation described in California Constitution Article DC, Section 9, acting for and on behalf of University of California, Davis Health (“UNIVERSITY”), and BriaCell Therapeutics Corp., a California private corporation, (“COMPANY”). UNIVERSITY and COMPANY are referred to individually as a “Party” and collectively as the “Parties”.
RECIPROCAL NONDISCLOSURE AGREEMENTReciprocal Nondisclosure Agreement • August 30th, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations • California
This Reciprocal Nondisclosure Agreement (“Agreement”) is made by and between The Regents of the University of California, a California constitutional corporation, acting for and on behalf of its University of California, Davis Health System (“UNIVERSITY”), and Briacell Therapeutics Corp., a private California corporation, (“COMPANY”). UNIVERSITY and COMPANY are referred to individually as a “Party” and collectively as the “Parties”.
Accelerated Clinical Trial AgreementAccelerated Clinical Trial Agreement • August 30th, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations
This Accelerated Clinical Trial (ACTA) Agreement (“Agreement”) is made as of September 12,2018 (“Effective Date”) by and between Providence Health & Services - Washington, dba Providence Regional Medical Center Everett (“Institution”), a non-profit corporation organized under the laws of the State of Washington, having an address at 1330 Rockefeller Avenue, Suite 440, Everett, Washington 98201, The Everett Clinic, PLLC, a Washington professional limited liability company with a place of business at 3901 Hoyt Avenue, Everett, WA 98201 (“Clinic”), Jason Lukas, M.D., an employee of Clinic, with a place of business at 1717 13th Street, Suite 300, Everett, Washington 98201 (“Principal Investigator”), and Cancer Insight, LLC, a limited liability company having its principal place of business at 1422 E Grayson, 3rd Floor, San Antonio, TX 78208 (“CRO”). CRO, Clinic, Principal Investigator, and Institution are herein referred to collectively as “Parties.” Individually, each of CRO, Clinic, Prin
EMPLOYMENT AGREEMENTEmployment Agreement • August 30th, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations • California
THIS AGREEMENT is entered into July 3, 2015, and is effective as of July 13, 2015 by and between BriaCell Therapeutics Corp., a Delaware corporation having an address at 8900 Wilshire Blvd., Beverly Hills, CA 90211 (the “Company”), and Markus Lacher, Ph.D. (“Employee”), having an address at 1353 Camino Peral, Unit B, Moraga, CA 94556.
CLINICAL STUDY AGREEMENTClinical Study Agreement • August 30th, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations • Texas
This Clinical Study Agreement (the “Agreement”) is entered into by and between BriaCell Therapeutics Corporation (the “Sponsor”), a publicly traded corporation with a principal place of business located at 820 Heinz Avenue, Berkeley, California 94710, and Cancer Insight, LLC (the “CRO”), a Texas limited liability company with a principal place of business located at 110 East Houston Street, San Antonio, Texas 78205 (each a “Party” and collectively, the “Parties”).
